FCM
TMO icon

Fourpath Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Fourpath Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.5M Sell
9,160
-247
-3% -$134K 0.65% 42
2025
Q4 		$5.45M Sell
9,407
-69
-0.7% -$39K 0.75% 35
2025
Q3 		$4.6M Sell
9,476
-1
-0% -$465 0.65% 38
2025
Q2 		$3.84M Sell
9,477
-142
-1% -$59.4K 0.6% 45
2025
Q1 		$4.79M Sell
9,619
-114
-1% -$61.7K 0.83% 32
2024
Q4 		$5.06M Sell
9,733
-207
-2% -$114K 0.94% 33
2024
Q3 		$6.15M Buy
9,940
+9,435
+1,868% +$5.59M 1.13% 24
2024
Q2 		$279K Sell
505
-29
-5% -$16.6K 0.21% 100
2024
Q1 		$310K Sell
534
-3
-0.6% -$1.68K 0.22% 92
2023
Q4 		$285K Buy
537
+72
+15% +$34.9K 0.19% 96
2023
Q3 		$235K Buy
465
+52
+13% +$27.7K 0.18% 104
2023
Q2 		$215K Sell
413
-23
-5% -$12.4K 0.26% 91
2023
Q1 		$251K Sell
436
-45
-9% -$25.4K 0.18% 107
2022
Q4 		$265K Sell
481
-70
-13% -$37.1K 0.19% 103
2022
Q3 		$279K Sell
551
-80
-13% -$44.8K 0.19% 99
2022
Q2 		$343K Sell
631
-28
-4% -$15.4K 0.21% 97
2022
Q1 		$389K Sell
659
-48
-7% -$27.6K 0.15% 109
2021
Q4 		$472K Buy
+707
New +$441K 0.18% 95

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fourpath Capital Management's TMO Position: Q1 2026 in Review

Fourpath Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 2.6% in Q1 2026, selling an estimated $134K and leaving 9,160 shares worth $4.5M. The position accounts for 0.65% of the portfolio, ranked #42.

Fourpath Capital Management first reported a position in TMO in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.15M in Q3 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Fourpath Capital Management held 9,160 shares of Thermo Fisher Scientific worth $4.5M as of Q1 2026.
  • Fourpath Capital Management sold 247 Thermo Fisher Scientific shares in Q1 2026, an estimated $134K.
  • Thermo Fisher Scientific made up 0.65% of Fourpath Capital Management's portfolio in Q1 2026, its #42 holding.
  • Fourpath Capital Management first reported a position in Thermo Fisher Scientific in Q4 2021 and has held it in 18 quarters since.
  • Fourpath Capital Management's Thermo Fisher Scientific position peaked at $6.15M in Q3 2024.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.